Literature DB >> 24984332

[Hepatitis C: who should be treated?].

Davor Stimac, Nikola Bradarić, Sandra Milić.   

Abstract

Therapy is strongly recommended in patients with acute infection, patients with elevated ALT levels, patients with normal ALT level and F > or = 2 METAVIR score, in genotype 1 nonresponders and relapsers to antiviral therapy with triple therapy (pegylated interferon, ribavirin, bocaprevir or telaprevir), in patients with compensated cirrhosis and patients on hemodialysis. It is possible to treat patients with HBV and HIV co-infection, patients with severe HCV extrahepatic manifestations and patients with transplanted liver. Drug users and alcoholics can be treated after 6-month abstinence, but also with supportive therapy. This therapy is not recommended in patients with fulminant hepatitis, patients with persistent normal ALT levels and without fibrosis, in kidney transplant recipients and in pregnant women.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24984332

Source DB:  PubMed          Journal:  Acta Med Croatica        ISSN: 1330-0164


  1 in total

1.  Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market.

Authors:  Diana Mance; Davor Mance; Dinko Vitezić
Journal:  Croat Med J       Date:  2016-12-31       Impact factor: 1.351

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.